Breaking News Instant updates and real-time market news.

TWLO

Twilio

$47.24

-3.56 (-7.01%)

, POT

Potash

$16.05

0.07 (0.44%)

08:45
10/14/16
10/14
08:45
10/14/16
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Twilio (TWLO) 93.96% +2.85, Potash (POT) 3.32% +0.95, Direxion Daily Small Cap Bear 3X Shares (TZA) 4.91% +0.33, Fitbit (FIT) 3.92% +0.31, Wynn Resorts (WYNN) 0.84% +0.27, SPDR S&P Metals and Mining (XME) 1.50% +0.23, Clovis Oncology (CLVS) 1.36% +0.21, JD.com (JD) 0.51% +0.16, United States Oil Fund LP (USO) 1.81% +0.15, and Opko Health (OPK) 5.11% +0.11.

TWLO

Twilio

$47.24

-3.56 (-7.01%)

POT

Potash

$16.05

0.07 (0.44%)

TZA

Small Cap Bear 3x

$28.95

0.7 (2.48%)

FIT

Fitbit

$13.34

-0.08 (-0.60%)

WYNN

Wynn Resorts

$94.95

-1.48 (-1.53%)

CLVS

Clovis

$33.12

0.44 (1.35%)

JD

JD.com

$26.27

-0.32 (-1.20%)

USO

United States Oil Fund

$11.49

0.06 (0.52%)

OPK

OPKO Health

  • 02

    Nov

  • 03

    Nov

  • 06

    Nov

  • 14

    Nov

  • 08

    Dec

  • 23

    Feb

TWLO Twilio
$47.24

-3.56 (-7.01%)

08/25/16
08/25/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cree (CREE) initiated with a Buy at Roth Capital. 2. Reynolds American (RAI) initiated with a Neutral at UBS. 3. Twilio (TWLO) initiated with a Hold at Argus. 4. Phillips 66 Partners (PSXP) initiated with a Neutral at Goldman. 5. WD-40 (WDFC) initiated with a Hold at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/18/16
JPMS
07/18/16
INITIATION
Target $39
JPMS
Neutral
Twilio initiated with a Neutral at JPMorgan
JPMorgan analyst Mark Murphy started Twilio with a Neutral rating and $39 price target.
07/18/16
07/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Twilio (TWLO) initiated with a Neutral at Goldman, an Outperform at William Blair, a Hold at Canaccord, a Sector Weight at Pacific Crest, a Market Perform at JMP Securities, and with a Neutral at JPMorgan. 2. Selecta Biosciences (SELB) initiated with a Buy at UBS, a Buy at Stifel, a Buy at Canaccord, and a Buy at Needham. 3. China Mobile (CHL) and China Telecom (CHA) assumed with a Buy at Jefferies. 4. NetEase (NTES) initiated with a Buy at Brean Capital. 5. Sysco (SYY) reinstated with a Hold at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/25/16
ARGS
08/25/16
INITIATION
ARGS
Hold
Twilio initiated with a Hold at Argus
Argus analysts Stephen Biggar and Mike Jaffe say that Twilio's opportunists should increase significantly going forward, but they predict that it will report losses "for several more quarters." The analysts say that the stock appears to be "fully valued" at current levels.
POT Potash
$16.05

0.07 (0.44%)

09/26/16
09/26/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AT&T (T) upgraded to Hold from Reduce at HSBC. 2. Potash (POT) upgraded to Positive from Neutral at Susquehanna with analyst Don Carson citing expected benefits from the company's proposed merger with Agrium (AGU), which he sees as having relatively low antitrust risk compared to the other mega-mergers being pursued in the Ag space. 3. Oshkosh (OSK) upgraded to Overweight from Neutral at JPMorgan and to Neutral from Underperform at Credit Suisse. 4. Marriott (MAR) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Thomas Allen citing strong unit growth. 5. NetApp (NTAP) upgraded to Buy from Hold at Cross Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/26/16
SUSQ
09/26/16
UPGRADE
Target $21
SUSQ
Positive
Potash upgraded to Positive at Susquehanna
As previously reported, Susquehanna analyst Don Carson upgraded Potash (POT) to Positive from Neutral, citing expected benefits from the company's proposed merger with Agrium (AGU), which he sees as having relatively low antitrust risk compared to the other mega-mergers being pursued in the Ag space. The firm, which also has a Positive rating for Agrium shares, raised its price target on Potash to $21 from $16 increased its price target on Agrium to $116 from $109.
10/07/16
RBCM
10/07/16
UPGRADE
RBCM
Outperform
Potash upgraded to Outperform from Sector Perform at RBC Capital
10/10/16
RBCM
10/10/16
UPGRADE
RBCM
Outperform
Potash upgraded on merger at RBC Capital
As noted on Friday, RBC Capital upgraded Potash (POT) to Outperform from Sector Perform. RBC Capital analyst Andrew Wong says that the estimated synergies of the Agrium (AGU)/Potash merger are "compelling." Wong calls the synergies "ambitious but achievable," and adds that the strategic benefits of the deal are "just as important as synergies." He thinks that the benefits of the deal "outweigh potential risks related to changing potash exposure." Target to $19 from $15.
TZA Small Cap Bear 3x
$28.95

0.7 (2.48%)

FIT Fitbit
$13.34

-0.08 (-0.60%)

10/07/16
CLVD
10/07/16
NO CHANGE
CLVD
Cleveland Research is cautious on Fitbit heading into Q4 and Q1 2027
Cleveland Research is cautious on Fitbit heading into Q4 and Q1 2027 saying new product uptake is muted and is concerned about inventory levels.
09/29/16
MZHO
09/29/16
NO CHANGE
MZHO
Fitbit Charge 2 checks remain strong, pullback unwarranted, says Mizuho
Mizuho's checks indicate Fitbit's Charge 2 sell through remains strong with favorable reviews, despite investor concerns. The firm's analyst views the pullback in Fitbit shares as unwarranted, especially since Q3 guidance assume minimal unit sales, and expects the Charge 2 to compete well and serve as a catalyst for Holiday season into Spring 2017. Mizuho continues to believe in Fitbit's long-term opportunity to maintain dominant share with in the increasingly growing global market for wearables while pursing opportunities in the healthcare industry.
09/29/16
MZHO
09/29/16
NO CHANGE
MZHO
Fitbit shares defended at Mizuho
09/29/16
09/29/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Coca-Cola (KO) downgraded to Hold from Buy at Stifel with analyst Mark Swartzberg saying that Coca-Cola's and Pepsi's organic EPS growth appears to be similar, but he believes that Pepsi is less vulnerable to foreign exchange fluctuations. 2. Fitbit (FIT) downgraded to Underweight from Sector Weight at Pacific Crest analyst Brad Erickson citing his channel checks which indicated that Charge 2, the company's flagship holiday product, is off to a slow start. 3. Discovery (DISCA) downgraded to Market Perform from Outperform at Barrington with analyst James Goss saying that Brexit and sports costs are dragging on its international results and foreign exchange tailwinds are moderating in many geographies. 4. Sonus (SONS) downgraded to Underperform from Market Perform at Cowen with analyst Paul Silverstein saying the firm's industry checks uncovered operational challenges and ongoing employee and executive churn. 5. Alcobra (ADHD) downgraded to Hold from Buy at Cantor and to Perform from Outperform at Oppenheimer. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
WYNN Wynn Resorts
$94.95

-1.48 (-1.53%)

08/12/16
UGAM
08/12/16
DOWNGRADE
UGAM
Hold
Wynn Resorts downgraded to Hold from Buy at Union Gaming
07/29/16
LYON
07/29/16
DOWNGRADE
LYON
Underperform
CLSA cuts Wynn Resorts to Underperform, says cannibalization risk underestimated
As previously reported, CLSA analyst Jon Oh downgraded Wynn Resorts to Underperform from Outperform. Along with its Q2 call, the company revealed that it expects to receive only 100 new tables for the Wynn Palace opening and expects to move a greater-than-expected 250 tables from Wynn Macau to Wynn Palace. While Oh does not think Wynn Palace's economics change in this scenario, he remains concerned that the market is underestimating the risk of self-cannibalization and a slower Macau EBITDA uplift. Oh keeps a $97 price target on the stock but believes the risk/reward ratio has become unfavorable following the stock's year-to-date rally of over 50%.
07/29/16
07/29/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. GrubHub (GRUB) downgraded to Neutral from Buy at BofA/Merrill, to Neutral from Buy at Monness Crespi, and to Hold from Buy at Maxim. 2. Ford (F) downgraded to Neutral from Buy at Goldman with analyst Patrick Archambault saying share outperformance over the next 6-12 months will be difficult following the carmaker's weaker than expected second quarter results and profit warning for 2016. 3. Starz (STRZA) downgraded to Hold from Buy at Pivotal Research with analyst Jeffrey Wlodarczak saying the Starz/Lionsgate (LGF) pro-forma entity is fairly valued. 4. Western Digital (WDC) downgraded to Hold from Buy at Cross Research with the firm saying the company is either unwilling or unable to provide a reasonable level of precision to the newly combined businesses with SanDisk and the higher than expected cost structure, combined with compensation increases will be a drag. 5. Wynn Resorts (WYNN) downgraded to Reduce from Neutral at Nomura and to Underperform from Outperform at CLSA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/12/16
08/12/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Macy's (M) downgraded to Neutral from Outperform at Macquarie with analyst Laurent Vasilescu saying the closure of 100 stores will have a greater impact than the $1B in 2017 sales projected by the company, and could be as much as $1.5B-$2B. 2. Wynn Resorts (WYNN) downgraded to Hold from Buy at Union Gaming. 3. Foot Locker (FL) downgraded to Mixed from Positive at OTR Global with the firm citing store manager checks that indicate product mix is pressuring sale growth. 4. Qualcomm (QCOM) downgraded to Neutral from Positive at Arete. 5. Barracuda (CUDA) downgraded to Underperform from Neutral at DA Davidson with analyst Mark Kelleher citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CLVS Clovis
$33.12

0.44 (1.35%)

10/04/16
PIPR
10/04/16
NO CHANGE
Target $42
PIPR
Neutral
Clovis price target raised to $42 from $14 at Piper Jaffray
Piper Jaffray analyst Steven Breazzano raised his price target for Clovis Oncology (CLVS) to $42 after taking a "comprehensive look" at the PARP inhibitor landscape in ovarian cancer and beyond. The company's PARP inhibitor rucaparib has demonstrated an active profile in ovarian cancer and all signs point to an approval in the 3L+ setting early next year, Breazzano tells investors in a research note. The analyst, however, believes the ultimate key is success in the earlier maintenance setting, and he thinks the race may still be Tesaro's (TSRO) niraparib's to lose. Breazzano keeps a Neutral rating on Clovis.
10/07/16
PIPR
10/07/16
NO CHANGE
PIPR
Neutral
Piper still sees Clovis' rucaparib getting broader indication than Lynparza
Piper Jaffray analyst Steven Breazzano said the rucaparib response rates in platinum resistant and platinum refractory patients of 25% and 0%, respectively, reported by Clovis Oncology (CLVS) are lower than some may have been expecting and "seemingly negative on the surface." However, he continues to believe rucaparib will be approved in BRCA patients who have received 2+ lines of therapy, which is an earlier and broader patient population than assigned to competitor AstraZeneca's (AZN) Lynparza, he tells investors. The ultimate market potential and key to success is the maintenance setting, for which TESARO's (TSRO) niraparib is still best-positioned, adds Breazzano, who keeps a Neutral rating on Clovis shares.
10/07/16
RHCO
10/07/16
NO CHANGE
Target $50
RHCO
Buy
Clovis selloff a buying opportunity, says SunTrust
SunTrust analyst Peter Lawson views today's selloff in shares of Clovis Oncology as a buying opportunity, saying today's concern "seems like noise." The analyst has a Buy rating on the stock with a $50 price target. Clovis is down 13%, or $4.64, to $31.13 but is well off the day's lows.
09/21/16
JANY
09/21/16
DOWNGRADE
Target $36
JANY
Neutral
Janney downgrades Clovis with buyout speculation at 'fever pitch'
Janney Capital analyst Roy Buchanan downgraded Clovis Oncology (CLVS) to Neutral from Buy with an increased fair value estimate of $36. Clovis is up 17c to $35.00 in late morning trading. In a research note partially titled, "May Be Right, May Be Crazy - M&A Speculation At Fever Pitch," Buchanan says there is a "finite chance" that Clovis will need to market its PARP inhibitor rucaparib by itself. He believes a late-2016 approval for rucaparib is likely. The analyst attributes his increased fair value estimate to "acquisition optionality." Reports of Takeda's (TKPYY) reserving up to $15B for acquisitions and Medivation's (MDVN) takeout have given Clovis shares a lift, Buchanan tells investors. The analyst adds that rumors surfaced yesterday of potential interest in the company from Eli Lilly (LLY).
JD JD.com
$26.27

-0.32 (-1.20%)

10/14/16
STFL
10/14/16
INITIATION
STFL
Buy
JD.com initiated at Stifel
As noted earlier, Stifel initiated JD.com with a $34 price target and a Buy rating. Analyst George Askew says that the company's "scale, management, brand, consumer trust and financial strength" will enable it to expand its e-commerce business and move into new areas.
09/20/16
09/20/16
DOWNGRADE

Neutral
JD.com downgraded on compeitive dynamics at MKM Partners
As previously reported, MKM Partners downgraded JD.com to Neutral from Buy. Analyst Rob Sanderson is concerned Alibaba (BABA) is preparing to increase competitive intensity, which could slow JD's margin ramp over the next several quarters.
10/13/16
STFL
10/13/16
INITIATION
Target $34
STFL
Buy
JD.com initiated with a Buy at Stifel
Stifel initiated JD.com with a Buy and a $34 price target.
09/20/16
MKMP
09/20/16
DOWNGRADE
MKMP
Neutral
JD.com downgraded to Neutral from Buy at MKM Partners
USO United States Oil Fund
$11.49

0.06 (0.52%)

OPK OPKO Health

10/07/16
JEFF
10/07/16
NO CHANGE
Target $10
JEFF
Hold
Palmetto no-coverage decision 'major setback' for OPKO, says Jefferies
Jefferies analyst Brandon Couillard views Palmetto's no-coverage decision yesterday for OPKO Health's 4Kscore prostate cancer test as a "major setback." Palmetto is a Medicare administrative contractor. The analyst views 4Kscore as a key near-term growth driver for OPKO and believes the company's local Medicare administrative contractor Novitas will likely follow suit. Without Medicare, 4K's commercial pathway from here is unclear, Couillard tells investors in a research note. He expects OPKO shares to trade lower on renewed reimbursement concerns. The analyst has a Hold rating on the name.
03/31/16
JEFF
03/31/16
NO CHANGE
Target $11
JEFF
Hold
Uncertainty may persist after Opko's Health drug setback, says Jefferies
Jefferies analyst Brandon Couillard says the FDA's complete response letter to Opko's Health's New Drug Application for Rayaldee as a treatment for secondary hyperparathyroidism was a surprise. While nonfatal, the analyst believes the setback adds a new level of uncertainty around a key value driver that could weigh on the stock well into the second half of 2016. Couillard has a Hold rating and $11 price target on the shares.
04/27/16
LTCO
04/27/16
NO CHANGE
Target $20
LTCO
Buy
OPKO Health resubmission of Rayaldee lifts overhang, says Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter believes OPKO Health resubmission of the New Drug Application for Rayaldee, which he notes came roughly within the timeframe he expected, lifts a potential overhang on the stock. The acceptance of the resubmission and issuance of a new PDUFA date suggest the issues identified by FDA at the third party supplier was limited and a suitable plan has been communicated, DeGeeter tells investors. The analyst keeps a Buy rating and $20 price target on OPKO shares.
06/03/16
STPT
06/03/16
INITIATION
Target $16
STPT
Buy
OPKO Health initiated with a Buy at Standpoint Research
Target $16.

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$63.82

0.04 (0.06%)

, ALXN

Alexion

$116.82

-1.9 (-1.60%)

04:55
04/23/17
04/23
04:55
04/23/17
04:55
Conference/Events
European Association for the Study of Liver »

International Liver…

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

CPHD

Cepheid

GALT

Galectin Therapeutics

$3.09

-0.14 (-4.33%)

GILD

Gilead

$65.93

-0.57 (-0.86%)

ICPT

Intercept

$107.89

0.7 (0.65%)

JWA

John Wiley & Sons; also tag JWB

NVS

Novartis

$73.40

-0.22 (-0.30%)

OSUR

OraSure

$12.67

0.03 (0.24%)

SIEGY

Siemens

$67.34

-0.197 (-0.29%)

VTL

Vital Therapies

$3.50

-0.1 (-2.78%)

ARWR

Arrowhead

$1.52

0.01 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 16

    May

  • 06

    Jun

  • 26

    Jun

  • 23

    Oct

AAPL

Apple

$142.27

-0.17 (-0.12%)

, FB

Facebook

$143.68

-0.12 (-0.08%)

13:57
04/22/17
04/22
13:57
04/22/17
13:57
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$142.27

-0.17 (-0.12%)

FB

Facebook

$143.68

-0.12 (-0.08%)

GOOG

Alphabet

$843.19

1.54 (0.18%)

GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

MSFT

Microsoft

$66.40

0.9 (1.37%)

STLD

Steel Dynamics

$35.37

0.46 (1.32%)

AKS

AK Steel

$6.72

-0.1 (-1.47%)

X

U.S. Steel

$30.42

-0.09 (-0.29%)

NUE

Nucor

$60.00

-0.35 (-0.58%)

CYH

Community Health

$8.24

-0.11 (-1.32%)

HCA

HCA Holdings

$83.55

-0.57 (-0.68%)

LPNT

LifePoint

$60.85

-0.7 (-1.14%)

THC

Tenet

$15.35

0.36 (2.40%)

UHS

Universal Health

$118.84

-0.29 (-0.24%)

HUM

Humana

$213.67

-0.57 (-0.27%)

BAC

Bank of America

$22.71

-0.36 (-1.56%)

C

Citi

$57.72

-0.69 (-1.18%)

GS

Goldman Sachs

$216.86

-1.2 (-0.55%)

JPM

JPMorgan

$84.52

-1.03 (-1.20%)

MS

Morgan Stanley

$41.80

-0.7 (-1.65%)

USB

U.S. Bancorp

$50.51

-0.17 (-0.34%)

WFC

Wells Fargo

$53.00

-0.5 (-0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 09

    May

  • 09

    May

  • 11

    May

  • 16

    May

  • 16

    May

  • 19

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 25

    May

  • 06

    Jun

  • 06

    Jun

  • 13

    Jun

  • 13

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 25

    Jul

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

JNS

Janus Capital

$13.15

-0.07 (-0.53%)

13:27
04/22/17
04/22
13:27
04/22/17
13:27
Conference/Events
Janus Capital to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ABT

Abbott

$43.53

-0.45 (-1.02%)

, ABBV

AbbVie

$63.82

0.04 (0.06%)

04:55
04/22/17
04/22
04:55
04/22/17
04:55
Conference/Events
National Kidney Foundation to hold clinical meeting »

NKF 2017 Spring Clinical…

ABT

Abbott

$43.53

-0.45 (-1.02%)

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

AMGN

Amgen

$160.41

-1.63 (-1.01%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

GSK

GlaxoSmithKline

$40.78

0.07 (0.17%)

HZNP

Horizon Pharma

$14.99

-0.25 (-1.64%)

MNK

Mallinckrodt

$43.52

-1.41 (-3.14%)

MRK

Merck

$61.89

-0.66 (-1.06%)

AUPH

Aurinia Pharmaceuticals

$7.11

0.11 (1.57%)

NXTM

NxStage Medical

$27.90

-0.19 (-0.68%)

PLX

Protalix

$1.02

0.02 (2.00%)

RTRX

Retrophin

$18.47

-0.37 (-1.96%)

SNY

Sanofi

$44.09

-0.7 (-1.56%)

SHPG

Shire

$171.94

0.08 (0.05%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$24.29

0.215 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 10

    May

  • 27

    May

  • 06

    Jun

  • 09

    Jun

  • 14

    Jun

  • 26

    Jun

  • 19

    Jul

  • 14

    Aug

  • 23

    Oct

ABBV

AbbVie

$63.82

0.04 (0.06%)

, ALXN

Alexion

$116.82

-1.9 (-1.60%)

04:55
04/22/17
04/22
04:55
04/22/17
04:55
Conference/Events
European Association for the Study of Liver »

International Liver…

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

CPHD

Cepheid

GALT

Galectin Therapeutics

$3.09

-0.14 (-4.33%)

GILD

Gilead

$65.93

-0.57 (-0.86%)

ICPT

Intercept

$107.89

0.7 (0.65%)

JWA

John Wiley & Sons; also tag JWB

NVS

Novartis

$73.40

-0.22 (-0.30%)

OSUR

OraSure

$12.67

0.03 (0.24%)

SIEGY

Siemens

$67.34

-0.197 (-0.29%)

VTL

Vital Therapies

$3.50

-0.1 (-2.78%)

ARWR

Arrowhead

$1.52

0.01 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 22

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 16

    May

  • 06

    Jun

  • 26

    Jun

  • 23

    Oct

RGEN

Repligen

$35.06

-0.78 (-2.18%)

19:19
04/21/17
04/21
19:19
04/21/17
19:19
Initiation
Repligen initiated at First Analysis »

Repligen initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 30

    May

  • 06

    Jun

TWTR

Twitter

$14.63

-0.02 (-0.14%)

18:07
04/21/17
04/21
18:07
04/21/17
18:07
Periodicals
Homeland Security investigates potential abuse in Twitter case, Reuters says »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$843.19

1.54 (0.18%)

, GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

17:46
04/21/17
04/21
17:46
04/21/17
17:46
Periodicals
Waymo:Uber misled court on Levandowski using LIDAR secrets, Bloomberg says »

According to Bloomberg,…

GOOG

Alphabet

$843.19

1.54 (0.18%)

GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 22

    May

CDNA

CareDx

$1.00

0.05 (5.26%)

17:33
04/21/17
04/21
17:33
04/21/17
17:33
Hot Stocks
CareDx receives expected letter from Nasdaq »

CareDx announced that, as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBX

Greenbrier

$44.45

-0.2 (-0.45%)

17:33
04/21/17
04/21
17:33
04/21/17
17:33
Hot Stocks
Greenbrier CEO intends to sell one-half of his position in company stock »

The CEO of The Greenbrier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

CDNA

CareDx

$1.00

0.05 (5.26%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Earnings
CareDx backs FY17 revenue view $45M-$50M, consensus $47.62M »

Revenue view excludes any…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNA

CareDx

$1.00

0.05 (5.26%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Earnings
CareDx reports Q4 adjusted EPS (13c), consensus (18c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMMA

Alliance MMA

$1.69

-0.05 (-2.87%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Hot Stocks
Alliance MMA announces shareholder filed lawsuit against the company »

Alliance MMA announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNA

CareDx

$1.00

0.05 (5.26%)

17:30
04/21/17
04/21
17:30
04/21/17
17:30
Hot Stocks
CareDx names Michael Bell CFO »

CareDx announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVO

Novo Nordisk

$35.88

-0.52 (-1.43%)

, XOMA

XOMA

$7.73

0.26 (3.48%)

17:22
04/21/17
04/21
17:22
04/21/17
17:22
Hot Stocks
Novo Nordisk terminates exclusive license agreement with XOMA »

On April 20, XOMA (XOMA)…

NVO

Novo Nordisk

$35.88

-0.52 (-1.43%)

XOMA

XOMA

$7.73

0.26 (3.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 07

    May

  • 18

    May

  • 06

    Jun

HH

Hooper Holmes

$0.72

-0.1973 (-21.44%)

17:21
04/21/17
04/21
17:21
04/21/17
17:21
Hot Stocks
Breaking Hot Stocks news story on Hooper Holmes »

John Pappajohn reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBMS

First Bancshares

$28.00

0.15 (0.54%)

17:14
04/21/17
04/21
17:14
04/21/17
17:14
Earnings
First Bancshares reports Q1 EPS 12 c with items, consensus 35c »

Reports Q1 provision for …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRWI

DragonWave

$1.23

-0.025 (-2.00%)

17:04
04/21/17
04/21
17:04
04/21/17
17:04
Hot Stocks
DragonWave did not regain compliance with Nasdaq listing standards »

DragonWave announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:02
04/21/17
04/21
17:02
04/21/17
17:02
Hot Stocks
Sears establishes special committee to market certain real estate properties »

Sears Holdings said its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Hot Stocks
Sears names Rob Riecker CFO »

Sears announced that Rob…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

UAL

United Continental

$69.56

-0.24 (-0.34%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Hot Stocks
UAL: employee incentive opportunity to be tied to 'customer experience' »

United Continental said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Earnings
Sears sees FY17 net income $185M-$285M »

"The retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

SHLD

Sears

$13.39

-0.25 (-1.83%)

16:59
04/21/17
04/21
16:59
04/21/17
16:59
Hot Stocks
Sears raises annualized cost savings target to $1.25B from $1B »

Sears Holdings provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

LTBR

Lightbridge

$1.25

-0.06 (-4.58%)

16:51
04/21/17
04/21
16:51
04/21/17
16:51
Hot Stocks
CEO of Lightbridge Seth Grae reports 5.1% stake in company »

As of March 22, Seth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IONS

Ionis Pharmaceuticals

$44.26

1.35 (3.15%)

16:46
04/21/17
04/21
16:46
04/21/17
16:46
Syndicate
Breaking Syndicate news story on Ionis Pharmaceuticals »

Ionis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.